VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

T cells offer several advantages for solid tumor immunotherapy, including innate tumor recognition, human leukocyte antigen-independent killing, and a reduced risk of graft-versus-host disease. Their ...

Digitized R&D workflows help cell therapy developers reduce manual data handling and accelerate biologics development.

A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, ...

Chimeric antigen receptor (CAR) T-cell therapies have transformed cancer and autoimmune disease treatment. Modified CAR proteins equip T cells with the ability to identify and eliminate cancer cells ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...